| This implies that liraglutide and semaglutide may be beneficial for patients with type 2 diabetes, irrespective of their baseline BP (Diabetes Obesity and Metbolism)
This short review is focused on some open questions emerging from the effort to fully understand the link between COVID-19 and diabetes, mainly in the context of possible harmful or beneficial effects of commonly used drugs in patients with diabetes on the course of COVID-19 infection (Journal of Endocrinological Investigation)
HHS/DKA occurred mostly in T1D and younger patients. However, both also occurred in T2D, which is of great importance in the treatment of diabetes. Better education programmes are necessary to prevent decompensation and comorbidities (Acta Diabetologica)
Once the COVID-19 pandemic is over, review of all the changes will be important, determining which should be permanently implemented. The learnings from COVID-19 should help prepare Australia for future pandemics or other major health crises (Diabetes Research and Clinical Practice)
GLP‐1 RA/SGLT2i combination therapy seems to reduce HbA1c, body weight and systolic blood pressure without increasing the risk for severe hypoglycemia compared to either GLP‐1 RA or SGLT2i. No robust conclusions can be made regarding long‐term effectiveness or effect on cardiovascular outcomes (Diabetes, Obesity and Metabolism)
Guidelines for early-onset adult type 2 diabetes are extrapolated predominantly from evidence in older individuals. Strategies to support the participation of individuals with early-onset adult type 2 diabetes in future research are imperative to ensure guidelines for these high-risk individuals are evidence-based (Diabetologia)
Use of SGLT2i improved cardiac function in diabetic patients, regardless of the presence of HF. The improvements were more prominent in HF patients, especially in those with HFrEF. These improvements in cardiac function would contribute to the clinical benefit of SGLT2i (Cardiovascular Diabetology)
| 
